Assembly Biosciences Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Assembly Biosciences stock.
View analyst ratings for Assembly Biosciences or view top-rated stocks.

Wall Street analysts have given Assembly Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Assembly Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Assembly Biosciences.

Assembly Biosciences, Inc. (NASDAQ:ASMB) released its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.10. Assembly Biosciences had a negative trailing twelve-month return on equity of 24.46% and a negative net margin of 78.57%.
View Assembly Biosciences' earnings history.

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ASMB stock has decreased by 74.0% and is now trading at $4.06.
View which stocks have been most impacted by COVID-19.

6 analysts have issued 1-year price targets for Assembly Biosciences' stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Assembly Biosciences' share price to reach $11.25 in the next twelve months. This suggests a possible upside of 177.1% from the stock's current price.
View analysts' price targets for Assembly Biosciences or view top-rated stocks among Wall Street analysts.

5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

Some companies that are related to Assembly Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of ASMB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Assembly Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.22%), Armistice Capital LLC (5.57%), Platinum Investment Management Ltd. (3.56%), Acadian Asset Management LLC (2.66%), Geode Capital Management LLC (1.64%) and Renaissance Technologies LLC (1.44%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, Luisa M Stamm, Richard James Colonno and William E Iv Delaney.
View institutional ownership trends for Assembly Biosciences.

ASMB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Armistice Capital LLC, Man Group plc, State Board of Administration of Florida Retirement System, Cubist Systematic Strategies LLC, AQR Capital Management LLC, Northern Trust Corp, and Walleye Capital LLC. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff, Luisa M Stamm, and William E Iv Delaney.
View insider buying and selling activity for Assembly Biosciences or view top insider-selling stocks.

ASMB stock was bought by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., BlackRock Inc., Acadian Asset Management LLC, PDT Partners LLC, Geode Capital Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., and Russell Investments Group Ltd..
View insider buying and selling activity for Assembly Biosciences or or view top insider-buying stocks.

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASMB stock can currently be purchased for approximately $4.06.

Assembly Biosciences has a market capitalization of $163.04 million and generates $79.11 million in revenue each year. The biopharmaceutical company earns $-62,150,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

Assembly Biosciences employs 139 workers across the globe.

The official website for Assembly Biosciences is www.assemblybio.com.

Assembly Biosciences is headquartered at 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]